What's more, consolidation durvalumab remarkably decreased the risk of disease progression in locally advanced NSCLC patients without sensitizing EGFR mutations (HR, 0.47; 0.36–0.60) but not in those with mutations (HR, 0.76; 0.35–1.64).23 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.